Celularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totalling 393,100 shares, a decline of 5.5% from the March 31st total of 415,800 shares. Approximately 3.7% of the company's stock are sold short. Based on an average daily trading volume, of 98,300 shares, the days-to-cover ratio is currently 4.0 days.
Celularity Price Performance
Shares of NASDAQ CELU traded up $0.03 during midday trading on Tuesday, reaching $3.03. The company's stock had a trading volume of 11,692 shares, compared to its average volume of 215,475. Celularity has a fifty-two week low of $1.59 and a fifty-two week high of $8.90. The stock has a 50 day simple moving average of $4.59 and a 200-day simple moving average of $3.33.
Institutional Trading of Celularity
An institutional investor recently raised its position in Celularity stock. IPG Investment Advisors LLC grew its holdings in Celularity Inc. (NASDAQ:CELU - Free Report) by 97.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 171,695 shares of the company's stock after purchasing an additional 84,928 shares during the period. IPG Investment Advisors LLC owned about 0.09% of Celularity worth $38,000 at the end of the most recent quarter. 19.02% of the stock is currently owned by institutional investors and hedge funds.
Celularity Company Profile
(
Get Free Report)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Further Reading
Before you consider Celularity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celularity wasn't on the list.
While Celularity currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
